ValitaCell and Intel Health & Life Sciences today announced a strategic collaboration to develop novel analytical solutions for biomanufacturing.
Today, many of the analytical tests or cell assays relied on to make decisions in biologics and Cell & Gene Therapy (C>) production use destructive stains or processes that can be both complex and time consuming. A major challenge lies in the consistent and scaled manufacturing of innovative Cell Therapies that have gained approval in recent years.
These processes are limited by slow, laborious, and highly variable characterisation methods, that can take longer than the manufacturing process itself. For these therapies to reach patients at scale, a new breed of analytics is required to enable advanced process control. This collaboration will leverage the power of imaging and Artificial Intelligence to put faster and more Sustainable tools into the hands of biomanufacturers.
Biotechnology company ValitaCell will provide biomanufacturing-centred AI expertise together with access to industrial test beds. ValitaCell have invested significantly in recruiting world-class AI talent to build novel tools to analyse biological cell images.
Intel Health & life Science have extensive experience engineering robust AI tools across the Health & Life Sciences industry and will develop the deployment software and hardware infrastructure to enable the global biopharmaceutical community to embed ValitaCell’s AI tools across their process analytics.
“ValitaCell have invested significant resources in our Artificial Intelligence capability. Between both companies, we have assembled a world-class team and we’re excited about the impact we can have on our industry and on patient’s lives” Dr. Jerry Clifford, CEO at ValitaCell.
Over the next number of years we look forward to expanding our collaborative network to address the most challenging manufacturing workflows and translational challenges. Our teams are extremely focussed on doing everything we can to ensure sustainable access to the world’s most innovative medicines. Whilst our current focus is on working with partners across the biologics and Cell & Gene Therapy manufacturing sectors, we’re looking to build a wider biomanufacturing ecosystem and as such, we welcome conversations with innovative businesses who share our mission.
“The biopharmaceutical industry is undergoing a remarkable transformation in innovation that is ignighting a new era of medicine. Intel is excited to collaborate to unleash the power of Artificial Intelligence and predictive analytics to transform cell & gene therapy manufacturing at scale.” Sandra Colner, Global Head of Lab & Life Sciences at Intel Corporation.